Premium
miR‐125a‐3p suppresses the growth and progression of papillary thyroid carcinoma cell by targeting MMP11
Author(s) -
Song Min,
Wang Na,
Li Zhen,
Zhang Yanfang,
Zheng Yingying,
Yi Pengfei,
Chen Jing
Publication year - 2020
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.29333
Subject(s) - cancer research , cell growth , downregulation and upregulation , thyroid carcinoma , thyroid cancer , biology , metastasis , transfection , cell , tumor progression , papillary thyroid cancer , cell migration , cancer , microbiology and biotechnology , cell culture , thyroid , gene , endocrinology , genetics
The dysregulation of miR‐125a‐3p has been observed in multiple tumor types. Nevertheless, the function of miR‐125a‐3p in papillary thyroid carcinoma (PTC) is yet to be explored. Herein, we find that miR‐125a‐3p is markedly downregulated in PTC tissues, and its level is inversely related to the histological grade of PTC. Upregulation of miR‐125a‐3p suppresses the pulmonary metastatic ability as well as the tumor growth of PTC cell in vivo. Consistently, the colony formation ability and other metastasis‐related traits of PTC cell are inhibited by miR‐125a‐3p transfection in vitro. In addition, we identify that matrix metalloprotease 11 (MMP11) is the direct target gene of miR‐125a‐3p, and that miR‐125a‐3p inhibits cell viability, migration, and invasiveness of PTC cell by reducing MMP11 expression in vitro. Together, these data testify that the miR‐125a‐3p/MMP11 axis plays vital roles in the growth and progression of human PTC cells.